Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study

Publication | Closed Access

DOI

Citations

References

2024

Year

G. Folprecht, Thierry André, Élena Elez, Eric Van Cutsem, Lars Henrik Jensen, Jaafar Bennouna, Guillermo Ariel Mendez, M. Schenker, Christelle de la Fouchardière, María Luisa Limón,

Zeitschrift für Gastroenterologie

MedicineImmunologyMetastatic Colorectal CancerColorectal CancerPathologyImmune Checkpoint InhibitorCheckmate 8HwCancer TreatmentOncologyVs Chemotherapy